Sox10 and S100 in the diagnosis of soft-tissue neoplasms
Take care, stay healthy, and thank you for reading
Florindo M (2014) Inflammatory cytokines and physical activity in multiple sclerosis
Vertebrate neurogenesis is counteracted by Sox13 activity
LLY also announced in mid-February 2024 that a phase 2 trial evaluating tirzepatide for liver disease metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), met its primary endpoint where up to 74% of participants achieved resolution of MASH with no worsening of fibrosis, compared to 13% on placebo
The Formulas (4)(7) were as follows: 1,i , 2,i were the inter-study variabilities, when available, they would be added into E max , and ET 50 , respectively